Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.75 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.66 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.66 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29593227 | 1.00 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL13539716 | 0.90 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3799848 | 0.90 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3794134 | 0.89 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL13539617 | 0.88 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL12614326 | 0.88 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL5546277 | 0.88 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL10236774 | 0.87 | HSP90AA1 (0.78) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL13539442 | 0.87 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3393574 | 0.86 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1TRAP1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168830-A1 | HEMTAC SMALL MOLECULE DEGRADATION AGENT AND USE THEREOF | 山东大学 | 2023-09-14 | — | — | WO | disclosed |
| US-20210085700-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20210085700-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| EP-3738594-A1 | TARGETED THERAPEUTICS HAVING AN HSP90 LIGAND AS BINDING MOIETY | Madrigal Pharmaceuticals, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10828315-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10828315-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3035938-B1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS INC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20170056510-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056510-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056510-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-02 | — | — | US | disclosed |
| WO-2010043865-A1 | INHIBITORS OF HSP90 | CHROMA THERAPEUTICS LTD (GB) | 2010-04-22 | — | — | WO | disclosed |
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2009-12-24 | — | — | US | disclosed |
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2009-12-24 | — | — | US | disclosed |
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2009-12-24 | — | — | US | disclosed |
| US-7544672-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544672-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544672-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1869027-A2 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | Conforma Therapeutics Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060223797-A1 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2006-10-05 | — | — | US | disclosed |
| WO-2006105372-A2 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885TRAP1 8/4885 |
| US-20060223797-A1 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885TRAP1 9/4885 |
| US-20210085700-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885TRAP1 4/4885 |
| US-10828315-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885TRAP1 4/4885 |
| US-20170056510-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885TRAP1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.